Denise Myshko

Counseling, psychotherapy, and mental health services provide the opportunity to develop coping skills and inspire hope; however, patients often experience hurdles to accessing such care. Among these obstacles are cost, unawareness that programs exist, the COVID-19 pandemic, and other external factors.

In a box, ready to be unpacked in his new office, are all the things patients have given Robert L. Coleman, MD, over the years. They include a jug of beer from a brewery in Arkansas, a golden ship from Kuwait, bottles from Serbia, art and books, and even a signed picture of Weird Al Yankovic.

Investigators of the phase 3 ULTRA-V trial are look-ing to leverage the synergistic capabilities of venetoclax for patients with chronic lymphocytic leukemia with the addition of the U2 regimen of ublituximab in combination with umbralisib.

Dual blockade of the RAF/MEK and FAK pathways presents an opportunity for investigators to enhance and expand the number of patients with recurrent low-grade serous ovarian cancer who can benefit from targeted therapies.

The chemotherapy regimen of FOLFOXIRI plus bevacizumab was found to be preferred in terms of antitumor activity compared with FOLFOXIRI plus cetuximab in patients with RAS wild-type, BRAF V600E–mutant metastatic colorectal cancer.

Investigators validated the safety and efficacy of anti-C-type lectin-like molecule-1-based CAR T cells in a small clinical trial of pediatric patients with relapsed/refractory acute myeloid leukemia.

The combination of nivolumab and ipilimumab continued to provide a durable, long-term overall survival benefit compared with chemotherapy after 4 years for patients with advanced non‒small cell lung cancer regardless of PD-L1 expression or histology.

Daiichi Sankyo Inc. is collaborating with Guardant Health Inc. to develop a companion diagnostic for fam-trastuzumab deruxtecan-nxki, which is being studied to treat patients with advanced metastatic HER2-mutated non‒small cell lung cancer.

Investigators are evaluating the addition of nivolumab to standard neoadjuvant therapy in patients with high-risk, estrogen-receptor–positive/ HER2-negative breast cancer to determine whether the PD-1 immune checkpoint inhibitor can improve recurrence rates.

Investigators are studying LN-145, a novel immunotherapy developed from autologous tumor-infiltrating lymphocytes, as a potential new option for patients with unresectable or metastatic non–small cell lung cancer after disease progression on a checkpoint inhibitor and chemotherapy.

In the United States, a geographic mismatch exists between the number of medical oncology and radiation providers and patients needing care, with more specialists clustered in urban and metropolitan areas.

Amgen has completed its planned acquisition of Five Prime Therapeutics for $38.00 per share in cash, or approximately $1.9 billion.

Investigators are exploring a dual HER2-targeting strategy that incorporates tucatinib into a novel combination as second-line therapy for patients with HER2-positive gastric and esophageal cancers.

Patients with non‒small cell lung cancer whose circulating tumor MET Exon 14 is undetectable following treatment with savolitinb are more likely to have positive outcomes.

Investigators have launched the Epidemiology of Young Lung Cancer study to identify risk factors that can help shed light on why lung cancer develops in the younger population.

The Canada Foundation for Innovation has awarded C$5,187,685 to the Canadian Cancer Trials Group at Queen’s University in Kingston, Ontario, Canada, to fund the infrastructure for a new research platform to coordinate the development of new cancer cell therapies.

Investigators are seeking to determine the optimal protocol for monitoring patients with pancreatic cysts to better identify neoplasms that are more likely to become malignant.

Despite many diversity initiative over the past 10 years, a lack of meaningful representation of certain racial and ethnic minorities continues in the oncology workforce.

Devimistat, a small molecule that targets enzymes involved in cancer cell metabolism, holds promise for older patients with relapsed or refractory acute myeloid leukemia who typically have a poor prognosis with standard-of-care chemotherapy

Treatment strategies for patients with breast cancer, especially the combination of anthracyclines and HER2-targeted therapies, come with an increased risk of heart failure and cardiac toxicity.

The introduction of new therapies for patients with recurrent HER2-positive metastatic breast cancer has resulted in a crowded landscape for third-line treatments and beyond, raising questions about how best to sequence a wealth of options.

Although scientific advances in hematology and oncology have been extraordinary, the US health care system faces significant challenges in ensuring that patients receive high-quality, cost-effective care.

ADP-A2M4CD8, a novel T-cell therapy, is being investigated in a range of tumor types that express MAGEA4, an antigen expressed in solid tumors that investigators say represents a promising target for cellular immunotherapy.

Robert L. Coleman, MD, discusses key data for these therapies and touched on emerging developments concerning new therapies in ovarian and endometrial cancers.

February 13, 2021 - Nivolumab following surgery extended disease-free survival compared with placebo for patients with muscle-invasive urothelial carcinoma.

Although safety remains a concern with gene therapy, investigators are breaking ground in cell and gene therapy, and many believe that ultimately, a string of cured cancers will follow.

Investigators are seeking to determine whether seribantumab, a novel monoclonal antibody, can effectively treat patients with solid tumors that harbor rare NRG1 fusions.

Investigators are seeking to determine whether amcenestrant can generate meaningful antitumor activity when administered as short-term preoperative therapy to postmenopausal patients with newly diagnosed early breast cancer.

Tepotinib demonstrated durable clinical activity in patients with MET exon 14 skipping non‒small cell lung cancer.

Using real-world data from more than 4000 patients with common cancers, an algorithm was able to detect variations in care that, if reduced, could result in a median savings of $26,773 per patient.